Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
NEW YORK, March 13, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NasdaqGS: SPPI -News). The investigation focuses on whether the Company and its executives violated federal securities laws.
On March 13, 2013, shares of Spectrum fell as much as 38 percent after the Company forecast a steep drop in full-year revenue as hospitals increasingly opt for a generic colon cancer treatment over its biggest-selling drug, Fusilev. Spectrum, which had said in February that it expected sales to rise this year, forecast on Tuesday that total sales would fall to $160 million-$180 million in 2013. CEO and President Shrotriya Rajesh C Md sold over $4 million dollars in shares at the end of December 2012.
If you are aware of any facts relating to this investigation, or purchased shares of Spectrum, you can assist this investigation by contacting either Peretz Bronstein of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email Peretz@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC